HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a price target of $38.
September 15, 2023 | 10:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Iovance Biotherapeutics (NASDAQ:IOVA) has been reiterated as a 'Buy' by HC Wainwright & Co. with a maintained price target of $38.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $38 indicates the firm's continued confidence in the stock's potential, which could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100